Author: Ravi Shankar

HANOI, Vietnam, Sept. 29, 2026 (GLOBE NEWSWIRE) — EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading Advanced Air Mobility (AAM) technology platform company, today announced that its Global Fast Track Program has expanded to Vietnam: Vietnam has become the second country to join the Program following Sri Lanka, with Hanoi as its first stop, marking EHang’s first city‑level partnership in the country. The Company’s partner, HungViet Technology and Investment Trading JSC (“HungViet”), has signed a Memorandum of Understanding (MOU) with the Hanoi Department of Science and Technology (“Hanoi DOST”) in Hanoi. In accordance with Hanoi’s dedicated procedures for regulatory sandbox testing, the parties will carry out low‑altitude economy sandbox testing of electric vertical take-off and landing (“eVTOL”) aircraft centered on the EH216‑S pilotless human‑carrying aircraft, exploring compliant validation pathways for safe operations. EHang will provide the EH216‑S aircraft and its technological systems in support of the sandbox testing.

(Photo: Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee; Cu Ngoc Trang, Director of Hanoi Department of Science and Technology, alongside relevant competent officials; Conor Yang, Chief Financial Officer of EHang; Dang Duc Dung, President & CEO of HungViet, and other representatives attended the signing ceremony.)

(Photo: Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee delivers remarks at the signing ceremony.)

Under the MOU, the Hanoi DOST will provide guidance for the application and approval of the sandbox testing, while HungViet, as the local implementing entity, will commit technical, financial and human resources starting from October 2026, prepare the sandbox application materials, and carry out controlled test flights upon receipt of the authorization decision. The EH216‑S pilotless human‑carrying aircraft, operational technology systems and personnel training support involved in the sandbox testing will be provided by EHang. Centered on the sandbox testing, the cooperation will advance in phases at Hoa Lac Hi-Tech Park: conducting controlled test flights of the EH216‑S, building an unmanned aircraft traffic management (UTM) model and an operations control center (OCC) model, while advancing operational technology training, the joint development of technical standards and regulations, and technical exchanges. The sandbox testing will proceed upon completion of the relevant application and approval procedures.

Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee, stated, “Hanoi is in a phase of rapid urban development, and the low‑altitude economy holds tremendous potential. We greatly appreciate EHang’s technical support and collaboration. The signing and execution of this project will strongly advance the development of Hanoi’s low‑altitude economy and science‑innovation industries, drive comprehensive urban development, and ultimately bring benefits to Hanoi residents. Innovative technologies such as pilotless aerial vehicles will also open brand‑new possibilities for Hanoi’s urban mobility and cultural‑tourism growth.”

Under the cooperation plan, the parties will start with regulatory sandbox testing and carry out phased technical verification of the human‑carrying and cargo‑carrying variants of the EH216‑series pilotless eVTOL aircraft in line with Vietnam’s local regulatory rules, real-world operating environments and business implementation conditions, steadily advancing commercial‑operation‑related work. Beyond Hanoi, EHang plans to further expand its business to key Vietnamese cities including Ho Chi Minh City and Da Nang, and to realize diversified commercial‑use scenarios centered around urban commuting and the development of popular tourist destinations.

Anchoring Southeast Asia as a Strategic Hub: EHang Accelerates Implementation of its Global Fast Track Program

On the sidelines of the 61st Conference of Directors General of Civil Aviation, Asia and Pacific Regions (DGCA/61), EHang held discussions with senior representatives of Malaysia’s civil aviation authority, as well as civil aviation directors and delegates from Laos, Fiji, Cambodia, the Philippines, Tonga, Vietnam, Maldives, Bhutan, Nepal and other countries. Participants explored viable paths to deploy regulatory sandbox mechanisms and the Fast Track Program within respective jurisdictions.

Vietnam’s cultural‑tourism market boasts strong growth momentum. According to official Vietnamese statistics, the country received nearly 21.2 million international inbound tourists in 2025, hitting an all‑time high. The booming tourism industry unlocks extensive market space for applications including pilotless eVTOL aerial sightseeing and urban low‑altitude mobility. The signing of the MOU in Hanoi also represents a key advance for EHang’s Global Fast Track Program in Southeast Asia.

Conor Yang, Chief Financial Officer of EHang, commented, “Expanding into overseas markets means far more than exporting aircraft hardware. What matters most is the deep alignment of technology and commercial operations with local regulatory systems. Safety and compliance are the bedrock for the commercial realization of AAM. EHang’s Global Fast Track Program is designed for the regulatory frameworks and market characteristics of individual countries and regions. Through sandbox testing, operational validation and collaboration with local partners, it connects technology, commercial operations and regulation to accelerate commercial roll‑out. Vietnam is a highly innovative and important market within ASEAN. We look forward to working solidly with the Hanoi government on testing and validation activities, accumulating valuable practical experience for the safe and orderly commercial deployment of pilotless eVTOL in the country, and advancing commercial opportunities for low‑altitude mobility across Southeast Asia.”

About EHang
EHang (Nasdaq: EH) is a global‑leading Advanced Air Mobility technology platform company dedicated to making safe, autonomous and eco‑friendly air mobility accessible to everyone. EHang focuses on the research, development and manufacturing of a diversified portfolio of pilotless electric vertical take‑off and landing (eVTOL) aerial vehicles, covering a wide range of application scenarios including aerial tourism, intra‑city commuting, inter‑city travel, logistics transportation and emergency firefighting. EHang’s flagship product, the EH216‑S, has obtained the world’s first type certificate (TC), production certificate (PC) and standard airworthiness certificate (AC) for pilotless passenger‑carrying eVTOL aircraft issued by the Civil Aviation Administration of China (CAAC), and has entered operation under China’s first batch of commercial operation qualifications for pilotless passenger‑carrying eVTOL. In addition, the Company’s long‑range VT35 model further extends inter‑city mobility scenarios, laying the foundation for a multi‑tiered low‑altitude mobility network. Leveraging its advanced autonomous flight technology and scalable operational infrastructure, EHang is redefining the transportation of people and goods — transcending cities, regions and natural barriers to usher in a new era of air mobility. For more information, please visit www.ehang.com.

Safe Harbor Statement
This press release may contain forward‑looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward‑looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “may” and other similar expressions. Statements that are not historical facts, including statements regarding management’s beliefs and expectations, are forward‑looking statements. Forward‑looking statements involve inherent risks and uncertainties. Many factors could cause actual results to differ materially from those contained in any forward‑looking statement, including but not limited to product certification, the Company’s expectations regarding demand for and market acceptance of its products, the commercialization of the Company’s autonomous aerial vehicle products and solutions and Advanced Air Mobility services, its relationships with strategic partners, and the litigation currently involving the Company and potential litigation. The Company’s management has made such forward‑looking statements based on current expectations, assumptions, estimates and projections. While the Company’s management believes that these expectations, assumptions, estimates and projections are reasonable, forward‑looking statements are only predictions of future events and involve known and unknown risks and uncertainties that are difficult for the Company’s management to control. These risks and uncertainties may cause EHang’s actual results of operations, performance or achievements to differ materially from those expressed or implied by any forward‑looking statements.

Media Contact: pr@ehang.com 
Investor Contact: ir@ehang.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/4953a6d8-2bb3-4bc3-a9a5-ec21eb70c8cc

https://www.globenewswire.com/NewsRoom/AttachmentNg/5eff6620-8226-46c4-aa87-4b0ebbb91363

HANOI, Vietnam, Sept. 29, 2026 (GLOBE NEWSWIRE) — EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading Advanced Air Mobility (AAM) technology platform company, today announced that its Global Fast Track Program has expanded to Vietnam: Vietnam has become the second country to join the Program following Sri Lanka, with Hanoi as its first stop, marking EHang’s first city‑level partnership in the country. The Company’s partner, HungViet Technology and Investment Trading JSC (“HungViet”), has signed a Memorandum of Understanding (MOU) with the Hanoi Department of Science and Technology (“Hanoi DOST”) in Hanoi. In accordance with Hanoi’s dedicated procedures for regulatory sandbox testing, the parties will carry out low‑altitude economy sandbox testing of electric vertical take-off and landing (“eVTOL”) aircraft centered on the EH216‑S pilotless human‑carrying aircraft, exploring compliant validation pathways for safe operations. EHang will provide the EH216‑S aircraft and its technological systems in support of the sandbox testing.

(Photo: Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee; Cu Ngoc Trang, Director of Hanoi Department of Science and Technology, alongside relevant competent officials; Conor Yang, Chief Financial Officer of EHang; Dang Duc Dung, President & CEO of HungViet, and other representatives attended the signing ceremony.)

(Photo: Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee delivers remarks at the signing ceremony.)

Under the MOU, the Hanoi DOST will provide guidance for the application and approval of the sandbox testing, while HungViet, as the local implementing entity, will commit technical, financial and human resources starting from October 2026, prepare the sandbox application materials, and carry out controlled test flights upon receipt of the authorization decision. The EH216‑S pilotless human‑carrying aircraft, operational technology systems and personnel training support involved in the sandbox testing will be provided by EHang. Centered on the sandbox testing, the cooperation will advance in phases at Hoa Lac Hi-Tech Park: conducting controlled test flights of the EH216‑S, building an unmanned aircraft traffic management (UTM) model and an operations control center (OCC) model, while advancing operational technology training, the joint development of technical standards and regulations, and technical exchanges. The sandbox testing will proceed upon completion of the relevant application and approval procedures.

Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee, stated, “Hanoi is in a phase of rapid urban development, and the low‑altitude economy holds tremendous potential. We greatly appreciate EHang’s technical support and collaboration. The signing and execution of this project will strongly advance the development of Hanoi’s low‑altitude economy and science‑innovation industries, drive comprehensive urban development, and ultimately bring benefits to Hanoi residents. Innovative technologies such as pilotless aerial vehicles will also open brand‑new possibilities for Hanoi’s urban mobility and cultural‑tourism growth.”

Under the cooperation plan, the parties will start with regulatory sandbox testing and carry out phased technical verification of the human‑carrying and cargo‑carrying variants of the EH216‑series pilotless eVTOL aircraft in line with Vietnam’s local regulatory rules, real-world operating environments and business implementation conditions, steadily advancing commercial‑operation‑related work. Beyond Hanoi, EHang plans to further expand its business to key Vietnamese cities including Ho Chi Minh City and Da Nang, and to realize diversified commercial‑use scenarios centered around urban commuting and the development of popular tourist destinations.

Anchoring Southeast Asia as a Strategic Hub: EHang Accelerates Implementation of its Global Fast Track Program

On the sidelines of the 61st Conference of Directors General of Civil Aviation, Asia and Pacific Regions (DGCA/61), EHang held discussions with senior representatives of Malaysia’s civil aviation authority, as well as civil aviation directors and delegates from Laos, Fiji, Cambodia, the Philippines, Tonga, Vietnam, Maldives, Bhutan, Nepal and other countries. Participants explored viable paths to deploy regulatory sandbox mechanisms and the Fast Track Program within respective jurisdictions.

Vietnam’s cultural‑tourism market boasts strong growth momentum. According to official Vietnamese statistics, the country received nearly 21.2 million international inbound tourists in 2025, hitting an all‑time high. The booming tourism industry unlocks extensive market space for applications including pilotless eVTOL aerial sightseeing and urban low‑altitude mobility. The signing of the MOU in Hanoi also represents a key advance for EHang’s Global Fast Track Program in Southeast Asia.

Conor Yang, Chief Financial Officer of EHang, commented, “Expanding into overseas markets means far more than exporting aircraft hardware. What matters most is the deep alignment of technology and commercial operations with local regulatory systems. Safety and compliance are the bedrock for the commercial realization of AAM. EHang’s Global Fast Track Program is designed for the regulatory frameworks and market characteristics of individual countries and regions. Through sandbox testing, operational validation and collaboration with local partners, it connects technology, commercial operations and regulation to accelerate commercial roll‑out. Vietnam is a highly innovative and important market within ASEAN. We look forward to working solidly with the Hanoi government on testing and validation activities, accumulating valuable practical experience for the safe and orderly commercial deployment of pilotless eVTOL in the country, and advancing commercial opportunities for low‑altitude mobility across Southeast Asia.”

About EHang
EHang (Nasdaq: EH) is a global‑leading Advanced Air Mobility technology platform company dedicated to making safe, autonomous and eco‑friendly air mobility accessible to everyone. EHang focuses on the research, development and manufacturing of a diversified portfolio of pilotless electric vertical take‑off and landing (eVTOL) aerial vehicles, covering a wide range of application scenarios including aerial tourism, intra‑city commuting, inter‑city travel, logistics transportation and emergency firefighting. EHang’s flagship product, the EH216‑S, has obtained the world’s first type certificate (TC), production certificate (PC) and standard airworthiness certificate (AC) for pilotless passenger‑carrying eVTOL aircraft issued by the Civil Aviation Administration of China (CAAC), and has entered operation under China’s first batch of commercial operation qualifications for pilotless passenger‑carrying eVTOL. In addition, the Company’s long‑range VT35 model further extends inter‑city mobility scenarios, laying the foundation for a multi‑tiered low‑altitude mobility network. Leveraging its advanced autonomous flight technology and scalable operational infrastructure, EHang is redefining the transportation of people and goods — transcending cities, regions and natural barriers to usher in a new era of air mobility. For more information, please visit www.ehang.com.

Safe Harbor Statement
This press release may contain forward‑looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward‑looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “may” and other similar expressions. Statements that are not historical facts, including statements regarding management’s beliefs and expectations, are forward‑looking statements. Forward‑looking statements involve inherent risks and uncertainties. Many factors could cause actual results to differ materially from those contained in any forward‑looking statement, including but not limited to product certification, the Company’s expectations regarding demand for and market acceptance of its products, the commercialization of the Company’s autonomous aerial vehicle products and solutions and Advanced Air Mobility services, its relationships with strategic partners, and the litigation currently involving the Company and potential litigation. The Company’s management has made such forward‑looking statements based on current expectations, assumptions, estimates and projections. While the Company’s management believes that these expectations, assumptions, estimates and projections are reasonable, forward‑looking statements are only predictions of future events and involve known and unknown risks and uncertainties that are difficult for the Company’s management to control. These risks and uncertainties may cause EHang’s actual results of operations, performance or achievements to differ materially from those expressed or implied by any forward‑looking statements.

Media Contact: pr@ehang.com 
Investor Contact: ir@ehang.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/4953a6d8-2bb3-4bc3-a9a5-ec21eb70c8cc

https://www.globenewswire.com/NewsRoom/AttachmentNg/5eff6620-8226-46c4-aa87-4b0ebbb91363

HANOI, Vietnam, Sept. 29, 2026 (GLOBE NEWSWIRE) — EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading Advanced Air Mobility (AAM) technology platform company, today announced that its Global Fast Track Program has expanded to Vietnam: Vietnam has become the second country to join the Program following Sri Lanka, with Hanoi as its first stop, marking EHang’s first city‑level partnership in the country. The Company’s partner, HungViet Technology and Investment Trading JSC (“HungViet”), has signed a Memorandum of Understanding (MOU) with the Hanoi Department of Science and Technology (“Hanoi DOST”) in Hanoi. In accordance with Hanoi’s dedicated procedures for regulatory sandbox testing, the parties will carry out low‑altitude economy sandbox testing of electric vertical take-off and landing (“eVTOL”) aircraft centered on the EH216‑S pilotless human‑carrying aircraft, exploring compliant validation pathways for safe operations. EHang will provide the EH216‑S aircraft and its technological systems in support of the sandbox testing.

(Photo: Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee; Cu Ngoc Trang, Director of Hanoi Department of Science and Technology, alongside relevant competent officials; Conor Yang, Chief Financial Officer of EHang; Dang Duc Dung, President & CEO of HungViet, and other representatives attended the signing ceremony.)

(Photo: Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee delivers remarks at the signing ceremony.)

Under the MOU, the Hanoi DOST will provide guidance for the application and approval of the sandbox testing, while HungViet, as the local implementing entity, will commit technical, financial and human resources starting from October 2026, prepare the sandbox application materials, and carry out controlled test flights upon receipt of the authorization decision. The EH216‑S pilotless human‑carrying aircraft, operational technology systems and personnel training support involved in the sandbox testing will be provided by EHang. Centered on the sandbox testing, the cooperation will advance in phases at Hoa Lac Hi-Tech Park: conducting controlled test flights of the EH216‑S, building an unmanned aircraft traffic management (UTM) model and an operations control center (OCC) model, while advancing operational technology training, the joint development of technical standards and regulations, and technical exchanges. The sandbox testing will proceed upon completion of the relevant application and approval procedures.

Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee, stated, “Hanoi is in a phase of rapid urban development, and the low‑altitude economy holds tremendous potential. We greatly appreciate EHang’s technical support and collaboration. The signing and execution of this project will strongly advance the development of Hanoi’s low‑altitude economy and science‑innovation industries, drive comprehensive urban development, and ultimately bring benefits to Hanoi residents. Innovative technologies such as pilotless aerial vehicles will also open brand‑new possibilities for Hanoi’s urban mobility and cultural‑tourism growth.”

Under the cooperation plan, the parties will start with regulatory sandbox testing and carry out phased technical verification of the human‑carrying and cargo‑carrying variants of the EH216‑series pilotless eVTOL aircraft in line with Vietnam’s local regulatory rules, real-world operating environments and business implementation conditions, steadily advancing commercial‑operation‑related work. Beyond Hanoi, EHang plans to further expand its business to key Vietnamese cities including Ho Chi Minh City and Da Nang, and to realize diversified commercial‑use scenarios centered around urban commuting and the development of popular tourist destinations.

Anchoring Southeast Asia as a Strategic Hub: EHang Accelerates Implementation of its Global Fast Track Program

On the sidelines of the 61st Conference of Directors General of Civil Aviation, Asia and Pacific Regions (DGCA/61), EHang held discussions with senior representatives of Malaysia’s civil aviation authority, as well as civil aviation directors and delegates from Laos, Fiji, Cambodia, the Philippines, Tonga, Vietnam, Maldives, Bhutan, Nepal and other countries. Participants explored viable paths to deploy regulatory sandbox mechanisms and the Fast Track Program within respective jurisdictions.

Vietnam’s cultural‑tourism market boasts strong growth momentum. According to official Vietnamese statistics, the country received nearly 21.2 million international inbound tourists in 2025, hitting an all‑time high. The booming tourism industry unlocks extensive market space for applications including pilotless eVTOL aerial sightseeing and urban low‑altitude mobility. The signing of the MOU in Hanoi also represents a key advance for EHang’s Global Fast Track Program in Southeast Asia.

Conor Yang, Chief Financial Officer of EHang, commented, “Expanding into overseas markets means far more than exporting aircraft hardware. What matters most is the deep alignment of technology and commercial operations with local regulatory systems. Safety and compliance are the bedrock for the commercial realization of AAM. EHang’s Global Fast Track Program is designed for the regulatory frameworks and market characteristics of individual countries and regions. Through sandbox testing, operational validation and collaboration with local partners, it connects technology, commercial operations and regulation to accelerate commercial roll‑out. Vietnam is a highly innovative and important market within ASEAN. We look forward to working solidly with the Hanoi government on testing and validation activities, accumulating valuable practical experience for the safe and orderly commercial deployment of pilotless eVTOL in the country, and advancing commercial opportunities for low‑altitude mobility across Southeast Asia.”

About EHang
EHang (Nasdaq: EH) is a global‑leading Advanced Air Mobility technology platform company dedicated to making safe, autonomous and eco‑friendly air mobility accessible to everyone. EHang focuses on the research, development and manufacturing of a diversified portfolio of pilotless electric vertical take‑off and landing (eVTOL) aerial vehicles, covering a wide range of application scenarios including aerial tourism, intra‑city commuting, inter‑city travel, logistics transportation and emergency firefighting. EHang’s flagship product, the EH216‑S, has obtained the world’s first type certificate (TC), production certificate (PC) and standard airworthiness certificate (AC) for pilotless passenger‑carrying eVTOL aircraft issued by the Civil Aviation Administration of China (CAAC), and has entered operation under China’s first batch of commercial operation qualifications for pilotless passenger‑carrying eVTOL. In addition, the Company’s long‑range VT35 model further extends inter‑city mobility scenarios, laying the foundation for a multi‑tiered low‑altitude mobility network. Leveraging its advanced autonomous flight technology and scalable operational infrastructure, EHang is redefining the transportation of people and goods — transcending cities, regions and natural barriers to usher in a new era of air mobility. For more information, please visit www.ehang.com.

Safe Harbor Statement
This press release may contain forward‑looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward‑looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “may” and other similar expressions. Statements that are not historical facts, including statements regarding management’s beliefs and expectations, are forward‑looking statements. Forward‑looking statements involve inherent risks and uncertainties. Many factors could cause actual results to differ materially from those contained in any forward‑looking statement, including but not limited to product certification, the Company’s expectations regarding demand for and market acceptance of its products, the commercialization of the Company’s autonomous aerial vehicle products and solutions and Advanced Air Mobility services, its relationships with strategic partners, and the litigation currently involving the Company and potential litigation. The Company’s management has made such forward‑looking statements based on current expectations, assumptions, estimates and projections. While the Company’s management believes that these expectations, assumptions, estimates and projections are reasonable, forward‑looking statements are only predictions of future events and involve known and unknown risks and uncertainties that are difficult for the Company’s management to control. These risks and uncertainties may cause EHang’s actual results of operations, performance or achievements to differ materially from those expressed or implied by any forward‑looking statements.

Media Contact: pr@ehang.com 
Investor Contact: ir@ehang.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/4953a6d8-2bb3-4bc3-a9a5-ec21eb70c8cc

https://www.globenewswire.com/NewsRoom/AttachmentNg/5eff6620-8226-46c4-aa87-4b0ebbb91363

• Affiliate partnership with Redbrick Mortgage Advisory gives SingSaver users bank-by-bank rate comparison and advice through to application
• The launch takes SingSaver into Singapore’s largest household debt category, worth S$296.4 billion, where the gap between bank home loan rates and the HDB concessionary rate of 2.6% can add up to hundreds of dollars a month for borrowers

SINGAPORE, Sept. 29, 2026 (GLOBE NEWSWIRE) — SingSaver, Singapore’s leading personal finance comparison platform and part of Nasdaq-listed MoneyHero Group (NASDAQ: MNY), today launched a Home Loans comparison category in partnership with Redbrick Mortgage Advisory. The launch takes SingSaver into the largest category of household debt in Singapore and extends its product suite beyond credit cards, personal loans, insurance and brokerage.

Under the partnership, SingSaver contributes its brand and high-intent user base, connecting Singaporeans researching home loans with Redbrick’s comparison and advisory service. Redbrick manages the underlying bank panel and broker relationships, handling the process from comparison through to application.

Home loans represent Singapore’s single largest household debt category. Outstanding home loans reached S$296.4 billion in the first quarter of 2026. This accounted for approximately 71% of total household debt. The balance has grown for ten consecutive quarters, according to data released by the Department of Statistics (SingStat) and the Monetary Authority of Singapore (MAS).

A Shifting Rate Environment

The partnership lands at a point when the cost of not comparing has become easy to quantify. Three-month compounded Singapore Overnight Rate Average (SORA), the benchmark banks use to price most floating-rate mortgages, stood around 1.19% in mid-September 2026. Bank mortgage packages have followed suit, with rates across major lenders now well below the HDB concessionary rate of 2.6%, which has not changed since Q2 of 2026.

For a borrower with S$800,000 outstanding, the difference between 2.6% and 1.4% is roughly S$454 a month, or about S$5,400 a year. On a S$300,000 HDB loan, it is closer to S$170 a month. That arithmetic is driving a refinancing wave, concentrated among HDB flat owners whose lock-in periods have expired and who are comparing bank packages for the first time.

“Home loans are the single biggest financial commitment most Singaporeans will make, yet the market has stayed fragmented and hard to compare. Redbrick is one of the most established names in mortgage advisory in Singapore, and this partnership closes a genuine gap in our platform at a time when falling rates are pushing more homeowners to actively shop around,” said Ayush Goyal, Managing Director at SingSaver.

“Redbrick’s role has always been to give Singaporean homeowners impartial, expert guidance through one of the biggest financial decisions they will make. This partnership puts that guidance in front of a much wider pool of homeowners, right at the point they start comparing their options, and lets more people access the high standard of advice we’ve built our name on,” said Eugene Huang, Co-founder and director of Redbrick Mortgage Advisory.

The launch builds on growth SingSaver has already seen in higher-ticket lending, including its personal loans and brokerage categories, and positions the platform in one of the largest consumer lending markets in Singapore.

The Home Loans category is now live on SingSaver’s website here.

About MoneyHero Group

MoneyHero Limited (NASDAQ: MNY) is a tech- and AI-powered personal finance aggregation and comparison platform that provides consumers with actionable insights to discover, compare, and choose the best financial products with confidence — bringing data intelligence and seamless digital access across insurance and banking solutions. The Company operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. MoneyHero had over 280 commercial partner relationships as at June 30, 2026, and had approximately 3.7 million Monthly Unique Users across its platform for the three months ended June 30, 2026. The Company’s backers include Peter Thiel—co-founder of PayPal, Palantir Technologies, and the Founders Fund—and Hong Kong businessman, Richard Li, the founder and chairman of Pacific Century Group. To learn more about MoneyHero and how the innovative fintech company is driving APAC’s digital economy, please visit www.MoneyHeroGroup.com.

About Redbrick Mortgage Advisory

Redbrick is Singapore’s largest independent mortgage advisory firm, renowned for its expertise in financial analysis and mortgage planning concepts. The firm provides unbiased property financing, mortgage advisory, and optimization services to its clients at no cost. By partnering with all leading banking and financial institutions in Singapore, Redbrick ensures that the latest information and resources are always at its fingertips, ready to be deployed for the benefit of its clients.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated benefits of the partnership and SingSaver’s expansion into the home loans category. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. MoneyHero Group undertakes no obligation to update these statements except as required by law.

Media Contact

Ellerton & Co. on behalf of SingSaver / MoneyHero Group
moneyhero@ellerton.sg

WINDSOR, Ontario, Sept. 28, 2026 (GLOBE NEWSWIRE) — NEXE Innovations Inc. (“NEXE”, the “Company”, “we”, “us” or “our”) (TSX.V: NEXE) (Frankfurt: NX5) (OTC: NEXNF), a compostable and innovative materials company, is pleased to announce its financial results for the three-month period and year ended May 31, 2026 (“Q4 2026” and “fiscal 2026”, respectively).

Fiscal 2026 was NEXE’s first full year of production of its current-generation, BPI-certified compostable coffee pod, which was commercialized in November 2024. Revenue for the year increased 121.2% to $680,363, and Q4 2026 revenue of $218,477 was the highest quarterly revenue in the Company’s history. Management believes the year’s results reflect improving unit economics as volumes scaled and a lower operating cost base. Subsequent to year-end, NEXE added new partners and based on current customer interest and commercial opportunities in progress, management currently expects annual pod volumes to exceed 15 million pods.

Q4 and Fiscal 2026 Results

• Revenue Growth: Revenue for Q4 2026 was $218,477, compared to $59,921 in Q4 2025. Volumes from a commercial partner’s transition to the NEXE platform (as described below under “Commercial Update” and first announced in March 2026) contributed to growth during the quarter, alongside repeat orders from existing partners. Revenue for fiscal 2026 was $680,363, compared to $307,543 in fiscal 2025, an increase of 121.2%, reflecting the first full year of production of the current-generation NEXE Pod, repeat orders across the partner base, the onboarding of a major new customer, and a growing SKU count.
   
• Gross Margin: Gross loss for fiscal 2026 narrowed 40.0% to $(283,714), compared to $(472,485) in fiscal 2025, as cost of goods sold increased 23.6% against revenue growth of 121.2%. As partner volumes increased through the year, per-pod unit costs declined by more than 30% year over year, which in management’s view was primarily attributable to higher production volumes, process optimization, and a more normalized order mix. Q4 2026 gross loss was $(244,490), compared to $(227,424) in Q4 2025.Management believes the narrowing of gross loss reflects the continued benefit of production scale and anticipates further improvement in unit economics as volumes continue to grow.
   
• Cost Control: Selling, general and administrative expenses declined 25.6% year over year to $2,968,620 in fiscal 2026 and declined 29.9% to $706,242 in Q4 2026. Total operating expenses for fiscal 2026 decreased 17.6% to $5,409,301, compared to $6,563,895 in fiscal 2025, and operating loss before other items improved 19.1% to $(5,693,015), compared to $(7,036,380).
   
• Net Loss: Net loss for Q4 2026 improved 8.7% to $(1,585,323), compared to $(1,736,866) in Q4 2025. Net loss for fiscal 2026 was $(5,624,480), compared to $(2,845,233) in fiscal 2025. The prior year included a $3,700,554 gain on the sale of the Surrey facility and $458,921 of other income, partially offset by $449,873 of related income tax expense; none of these items recurred in fiscal 2026.
   
• Balance Sheet: NEXE ended fiscal 2026 with cash and cash equivalents of $5.4 million and GIC investments of $3.7 million and working capital of $8.5 million. Cash used in operating activities decreased to $3.3 million from $3.8 million in fiscal 2025. Management believes the Company’s existing financial resources, combined with projected cash inflows, are sufficient to meet its operating and capital requirements for at least 12 months. The Company has minimal capex requirements, and a minimal debt position related to an interest free government loan. The Company also maintains a 54,000-square-foot advanced manufacturing facility (including real estate) based in Windsor, Ontario. The facility is vertically integrated and is equipped for compounding resin, injection molding key components of NEXE’s proprietary single-use fully compostable pod, and dosing and sealing the pods for commercialization.

Commercial Update: Management Expects Annual Pod Volumes to Exceed 15 Million

The partner transition first announced in March 2026, under which a key commercial partner committed to moving the majority of its single-serve coffee pod volumes from plastic to NEXE’s BPI-certified compostable platform, is now under way. The identity of this partner has not been disclosed for commercial confidentiality reasons.. In June 2026, the Company reported that additional purchase orders had been placed and that two additional brands, one Canadian and one U.S.-based, had begun transitioning to the NEXE platform with anticipated combined volumes of approximately 1.5 million pods annually.

Subsequent to year-end, NEXE entered into a partnership with Just Us! Coffee Roasters, an East Coast fair-trade organic coffee co-op that previously had no single-serve offering. To date, NEXE has delivered approximately 200,000 pods to Just Us!. Management believes this relationship reflects an emerging opportunity for the Company – sustainability-focused coffee brands that have historically avoided single-serve formats can now consider entering the category while maintaining their sustainability positioning. NEXE has also onboarded a U.S. coffee chain with multiple locations, including New York City and Boston, and is in discussions with several additional coffee companies, including an established coffee brand.

NEXE has previously provided guidance that it expects an annual pod volume run-rate of 10 million to 15 million pods. Based on current customer interest and opportunities in progress, management now expects to exceed the upper end of this range.

Outlook

Management’s focus for fiscal 2027 is converting the Company’s commercial pipeline into higher production volumes while continuing to pursue improvements in manufacturing efficiency and unit economics. The Company intends to continue pursuing a capital-efficient platform strategy, partnering with established coffee operators, roasters, and distributors who bring existing customer relationships, established distribution channels, and volume potential. Management expects that sales will increase and operating performance will improve as the Company’s customer base and production volumes scale.

The Company is also evaluating strategic opportunities that management anticipates would accelerate commercialization and enhance shareholder value, including potential partnerships, licensing arrangements, and other capital-efficient growth initiatives.

“Fiscal 2026 was our first full year producing the current-generation NEXE Pod, and revenue more than doubled,” said Ash Guglani, President of NEXE. “Unit costs declined as volumes built, the partner that committed to transitioning the majority of its pods to NEXE started the process, and we have added new partners since year-end. Our priority for fiscal 2027 is to continue growing our revenue base and converting our commercial pipeline into production volume.”

The Company’s audited consolidated financial statements for the year ended May 31, 2026 and related management’s discussion and analysis are available on NEXE’s SEDAR+ profile at www.sedarplus.ca and the Company’s website at www.nexeinnovations.com.

*NEXE Innovations Inc. is not affiliated with, endorsed, or sponsored by Keurig®. Keurig® is a registered trademark of Keurig Dr Pepper Inc.

**NEXE Innovations Inc. is not affiliated with, endorsed, or sponsored by Nespresso®. Nespresso® is a registered trademark of Société des Produits Nestlé S.A

About NEXE Innovations Inc.

NEXE Innovations is focused on providing innovative compostable material solutions and packaging to the B2B segment to help businesses achieve their sustainability goals. NEXE Innovations has developed a proprietary and patented compostable material that can withstand heat, pressure, and water. Our flagship product, the NEXE Pod, a BPI-certified compostable coffee pod, showcases our material’s durability and is an ideal substitute for plastic.  The NEXE pod is compatible with major coffee brewing machines and is manufactured at NEXE’s vertically integrated facility based in North America. Discover our innovative approach to sustainability at www.nexeinnovations.com and join our journey on social media @nexeinnovations. #compostablecoffeepods #sustainability #greentech

On behalf of the Company:

Ash Guglani
President & Director

For investor relations contact:

Kam Mangat
Vice President, Investor Relations & Corporate Strategy
invest@nexeinnovations.com

For media relations contact: media@nexeinnovations.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this release are forward-looking statements or information, which include, but are not limited to, statements regarding anticipated production volumes, including expected annual pod volumes relative to the Company’s previously stated range, expected demand from existing and prospective customers, the scope and timing of customer commitments and partner transitions, Company’s commercialization strategy, expected improvements in manufacturing efficiency and unit economics, the evaluation and pursuit of strategic opportunities, including partnerships and licensing arrangements, expected operating and capital requirements, including management’s belief that the Company’s existing financial resources are sufficient to meet its operating and capital requirements for at least 12 months, and the Company’s ability to execute its business strategy. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business and economic conditions in the markets in which the Company operates, the Company’s ability to execute on its business strategy, maintain and grow partnerships, onboard new customers, and respond to market conditions, the Company’s ability to achieve anticipated production volumes and improve unit economics, the availability and cost of raw materials and changes in consumer demand for compostable products, and those risks set out in the Company’s management’s discussion and analysis for the year ended May 31, 2026 under the headings “Risk and Uncertainties”. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the demand for its products, anticipated costs, and the ability to achieve goals, that the Company’s current partners will continue to increase order volumes, that new customer relationships will result in recurring revenue, that the Company will be able to maintain or reduce per-pod unit costs as production scales, and that general economic and market conditions will not deteriorate. Factors that could cause the actual results to differ materially from those in forward-looking statements include, without limitation, loss of key customer relationships, disruptions to supply chains or manufacturing operations, adverse changes to tariff or trade policies, general economic, market or business conditions, and other factors beyond the Company’s control. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This press release was published by a CLEAR® Verified individual.

BANGKOK, Sept. 29, 2026 (GLOBE NEWSWIRE) — NewGenIvf Group Limited (NASDAQ: NIVF) (the “Company”), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $1.25 million, before deducting placement agent fees and other offering expenses payable by the Company.

The offering consists of 17,857,143 Ordinary Shares or Pre-Funded Warrants in lieu thereof. The public offering price per Common Share is $0.07 (or $0.06999 for each Pre-Funded Warrant, which is equal to the public offering price per Ordinary Share to be sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Warrant sold in the offering, the number of Ordinary Shares in the offering will be decreased on a one-for-one basis.

Aggregate gross proceeds to the Company are expected to be approximately $1.25 million. The transaction is expected to close on or about September 30, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering, together with its existing cash, for investment in K25.ai, restructuring of debt securities, working capital including manufacturing and deployment of Nodexus machines in the cell-sorting business, and general corporate purposes.

Aegis Capital Corp. is acting as the exclusive placement agent for the offering. Han Kun Law Offices LLP is acting as U.S. counsel to the Company. Kaufman & Canoles, P.C. is acting as U.S. counsel to Aegis Capital Corp.

A registration statement on Form F-1 (No. 333-298442) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 20, 2026 was declared effective by the SEC on September 28, 2026. The offering is being made only by means of a prospectus. A final prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010. Before investing in this offering, interested parties should read in their entirety the prospectus, which provides more information about the Company and such offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About NewGen

NewGenIVF Group is a technology-forward, diversified growth company, pursuing opportunities across real estate development, digital asset innovation and reproductive health solutions. The Company operates through NewGenProperty, focused on real estate development projects in the UAE’s Ras Al Khaimah Emirate; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products and solutions. NewGenIVF’s legacy business includes IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. Information contained on, or accessible through, the Company’s website is not incorporated by reference into this press release.

Forward-Looking Statements

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Contact

ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: Newgenivf.IR@icrinc.com

BEIJING, Sept. 28, 2026 (GLOBE NEWSWIRE) — Julong Holding Limited (“Julong” or the “Company”) (Nasdaq: JLHL), a growth-oriented provider of intelligent integrated solutions, today announced that, on September 28, 2026, it entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors for a private placement (the “Private Placement”) of the Company’s securities.

Under the terms of the Securities Purchase Agreement, the Company agreed to issue and sell (i) 750,000 Class A ordinary shares (the “Class A Ordinary Shares”), par value US$0.0001 per share, of the Company (the “Initial Shares”), at a purchase price of US$0.300 per share, and (ii) 2,250,000 pre-funded warrants to purchase up to an aggregate of 2,250,000 Class A Ordinary Shares (the “Pre-Funded Warrants,” together with the Initial Shares, the “Securities”), at a purchase price of US$0.299 per pre-funded warrant. The Pre-Funded Warrants have an exercise price of US$0.001 per share, are immediately exercisable, and may be exercised at any time until exercised in full. The aggregate gross proceeds of the Private Placement are US$897,750.

The Private Placement is expected to close on or about September 29, 2026, subject to satisfaction or waiver of the conditions precedent set forth in the Securities Purchase Agreement. Net proceeds from the Private Placement, after deducting offering expenses, are approximately US$828,000. The Company intends to use such proceeds for general corporate purposes. The Company’s management retains discretion over the use and timing of the proceeds.

The Securities offered in this Private Placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any applicable state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The investors represented that they were accredited investors within the meaning of Rule 501(a) of Regulation D of the Securities Act and were acquiring the Securities for investment only and with no present intention of distributing any of such Securities or any arrangement or understanding regarding the distribution thereof. Additional details regarding the Private Placement are set forth in the Company’s Current Report on Form 6-K filed with the U.S. Securities and Exchange Commission.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Julong

Founded in 1997, Julong is a growth-oriented professional provider of intelligent integrated solutions to public utilities, commercial properties, and multifamily residential properties operating at scale in China. The Company’s comprehensive suite of intelligent integrated solutions includes systems for intelligent security, fire protection, parking, toll collection, broadcasting, identification, data room, emergency command, and city management. Since its inception, Julong has focused on the successful and on-time execution of complex projects, through its “deliveries before deadline” and “customers first” initiatives. As Julong continues to cross-sell its service and solution offerings and advance its purpose-built technologies, the Company is well-positioned to achieve economies of scale and capture future opportunities.

For more information, please visit: ir.julongzx.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “will,” “would,” “may,” “expects,” “anticipates,” “aims,” “future,” “continues,” “could,” “should,” “target,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements, and include, but are not limited to, statements regarding the expected closing of the Private Placement and the use of proceeds therefrom. Forward-looking statements involve inherent risks and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the risk that the Private Placement may not close on the anticipated timeline or at all, and other factors discussed under “Risk Factors” in the Company’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

In China:

Investor Relations:
Email: ir@julongzx.com

Piacente Financial Communications
Jenny Cai
Tel: +86 (10) 6508-0677
Email: julong@thepiacentegroup.com

In the United States:

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
Email: julong@thepiacentegroup.com

All measurable sequencing metrics show profound improvement over Platinum Pro

BRANFORD, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced interim development results comparing its next-generation Proteus™ platform with its commercially available Platinum^® Pro instrument. Using a developmental sequencing kit that detects 18 amino acids, Proteus significantly outperformed Platinum Pro across every key measure, from sequencing scale and accuracy to peptide identification and protein sequence coverage, even though the Proteus instrument, consumable, loading protocol and analysis software are still in development and not yet fully optimized. The data will be presented by Jeff Hawkins, President and Chief Executive Officer, at a lunchtime seminar at the 2026 World HUPO Congress in Singapore on Tuesday, September 29, 2026, at 12:15 Singapore Time (SGT) in Room 330.

“These interim results show that Proteus is a fundamentally superior platform technology, not simply a larger version of Platinum Pro,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “Proteus improves every fundamental driver of sequencing performance, including scale, signal quality, conversion and accuracy, and those gains compound into dramatically more data. What makes these results even more encouraging is that this Proteus system has not yet been fully optimized, and we expect further improvements ahead of launch.”

In a control peptide study designed to evaluate fundamental performance independent of sample preparation, Proteus delivered a median of 30 times more alignments than Platinum Pro from a single chamber, identified all six control peptides in every run, and achieved a 4.8-fold lower median false discovery rate (1.36% in Proteus versus 6.58% in Platinum Pro). Based on these single-chamber results, the Company projects that a full four-chamber Proteus run could deliver approximately 60 times more alignments than a two-chamber Platinum Pro run. In protein mixtures prepared with a commercial library prep kit, Proteus identified 1.6 to 2.0 times more peptides than Platinum Pro. Further, in a 24-protein panel not previously sequenced on either platform, Proteus detected all 24 proteins, compared with an average of 20.3 on Platinum Pro, and detected 4.3 times more amino acids per run, with higher per-residue detection across the amino acids measured, including cysteine and histidine, which were detected only on Proteus. A copy of the presentation will be available in the Events & Presentations section of the Quantum-Si investor relations website, and an audio recording will be added once available.

Figure 1: Reported alignments per single-chamber run, control peptide study (n = 4 runs per platform)

Figure 2: 24-protein panel results from a single chamber, proteins not previously sequenced on either platform

About Quantum-Si Incorporated
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time, kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products, services and applications, its anticipated cash runway, the anticipated timing of product launches and product capabilities, including the expected launch of Proteus in the second quarter of 2027, the expected performance of Proteus relative to Platinum Pro, including projected full-run performance, and the expected amino acid detection capabilities of Proteus, including the expected detection of all 20 amino acids in the commercial kit at launch, the Company’s current belief regarding remaining technical challenges associated with Proteus commercialization, the expected timing and successful completion of system integration, optimization, verification, validation and launch-readiness activities, the expected benefits of the Company’s development-process, organizational and cost-control actions, including the reduction in force, and any financial guidance.

These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Many of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth and retain its key employees; the Company’s ongoing leadership transitions and succession planning; the Company’s ability to successfully implement organizational changes, including workforce reductions, cost-control actions and development-process improvements, without disrupting product development, launch readiness, employee retention or customer engagement; the possibility that additional technical, integration, performance, reliability, verification, validation or launch-readiness challenges may arise or take longer or cost more to address than expected; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities, including the use and benefit of artificial intelligence in these and other activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future, including Proteus; the potential attributes and benefits of the Company’s commercialized Platinum Pro protein sequencing instruments and kits and the Company’s other products (including Proteus) once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s defense and initiation of litigation matters; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Investor and Media Contact
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/b0d73d5e-1892-4005-8408-5bdb14565852

https://www.globenewswire.com/NewsRoom/AttachmentNg/7746d376-a9ee-470f-bac3-57aa70ceb458

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio^®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Euretina Innovation Spotlight (EIS) being held on September 30, 2026, and Euretina being held on October 1-4, 2026, in Vienna, Austria.

EIS Presentation Details
Session: EURETINA Innovation Spotlight – Inherited and Rare Retinal Diseases
Title: Belite Bio Company Overview
Presenter: Hendrik Scholl, M.D., Chief Medical Officer, Belite Bio
Date and Time: September 30, 2026, 2:28 – 3:06 p.m. CEST
Location: Vienna Congress & Convention Center, Room 1/Hall A

Euretina Presentation Details
Session: EURETINA Free Paper 47 – Inherited Retinal Disease
Title: Topline Results from the Phase 3 DRAGON Study of Tinlarebant for Adolescent Stargardt Disease
Presenter: Michel Michaelides, M.D., Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom
Date and Time: October 4, 2026, 1:20 – 1:27 p.m. CEST
Location: Vienna Congress & Convention Center, Free Paper Forum 2

About Tinlarebant (a/k/a LBS-008)

Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in Stargardt disease type 1 (STGD1) and also contribute to disease progression in geographic atrophy (GA), or advanced dry age-related macular degeneration (AMD). Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Disease Designation in the U.S., Orphan Drug Designation in the U.S., Europe, Japan, and Switzerland, and Sakigake Designation in Japan for the treatment of STGD1.

About Stargardt Disease

STGD1 is the most common inherited macular dystrophy in both adults and children. The disease is caused by mutations in a retina-specific gene (ABCA4), which results in progressive accumulation of bisretinoids leading to retinal cell death and progressive loss of central vision. The fluorescent properties of bisretinoids and the development of high-resolution retinal imaging systems have helped ophthalmologists identify and monitor disease progression. Currently, there are no approved treatments for STGD1.

About Belite Bio

Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the Company’s new drug application for tinlarebant for the treatment of STGD1 was accepted by the U.S. Food and Drug Administration (FDA), with priority review, in August 2026. The FDA has set a Prescription Drug User Fee Act date of February 12, 2027. Tinlarebant is also currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contact:
ir@belitebio.com

— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —

— Application supported by SAFFRON, the first global Phase III trial to demonstrate statistically significant and clinically meaningful improvements in progression-free and overall survival in this setting —

— SAFFRON builds on evidence from the SACHI Phase III and SAVANNAH Phase II trials —

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that AstraZeneca has submitted a New Drug Application (“NDA”) to the US Food and Drug Administration (“FDA”) for ORPATHYS^® (savolitinib) plus TAGRISSO^® (osimertinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) whose tumors have MET overexpression or amplification, and who had disease progression on or after an epidermal growth factor receptor (“EGFR”) tyrosine kinase inhibitor (“TKI”) therapy.

The NDA is supported by the global SAFFRON Phase III trial. SAFFRON showed ORPATHYS^® plus TAGRISSO^® demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (“PFS”) and overall survival (“OS”) versus doublet platinum-based chemotherapy in patients who progressed on treatment with TAGRISSO^®. The safety profile was consistent with the known profiles of each medicine, and there were no new safety concerns. These results will be presented in a Presidential Symposium at the upcoming European Society for Medical Oncology (ESMO) Congress 2026.

Third-generation EGFR tyrosine kinase inhibitors (“TKIs”) have significantly improved outcomes for patients with EGFRm NSCLC. However, MET overexpression or amplification is one of the most common mechanisms of resistance on third-generation EGFR-TKI treatment. MET-driven progression is associated with poor prognosis, and there remains a significant unmet need for effective and well-tolerated treatment options in this setting.

Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, said: “This filing is an important step toward potentially bringing ORPATHYS^® plus TAGRISSO^® to patients in the US, after its approval in China based on the SACHI Phase III trial. The success of the global SAFFRON Phase III trial reflects the long-standing collaboration between HUTCHMED and AstraZeneca in addressing MET-driven progression in EGFR-mutated lung cancer. We remain committed to supporting the regulatory review and making this biomarker-directed, chemotherapy-free oral combination available to eligible patients.”

ORPATHYS^® is being jointly developed by AstraZeneca and HUTCHMED and is commercialized by AstraZeneca.

About NSCLC and MET aberrations

Lung cancer is the leading cause of cancer death globally, accounting for almost one in four (23%) cancer deaths.¹ Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% of patients diagnosed with NSCLC.² Approximately 75% of NSCLC patients are diagnosed with advanced disease.³ Additionally, about 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia, have EGFRm NSCLC.^​4,5,6

MET is a tyrosine kinase receptor that has an essential role in normal cell development.⁷ MET overexpression or amplification can lead to tumor growth and the metastatic progression of cancer cells.^7,8 An estimated 34% of tumors will develop high levels of MET overexpression or amplification after progression on a third-generation EGFR TKI.¹

About SAFFRON

SAFFRON is a randomized, open-label, multi-center, global Phase III trial studying the efficacy of ORPATHYS^® (300 mg twice daily) added to TAGRISSO^® (80 mg once daily) versus doublet platinum-based chemotherapy in 338 patients with EGFRm, locally advanced or metastatic NSCLC with MET overexpression or amplification whose disease progressed following first- or second-line treatment with TAGRISSO^®. The trial enrolled patients in 230 centers across 29 countries, including in North America, Europe, South America and Asia. The primary endpoint is PFS and key secondary endpoint includes OS.

Patients were prospectively selected for SAFFRON using the high MET level cut-offs identified in the SAVANNAH Phase II trial. ​In SAVANNAH, MET overexpression or amplification levels were determined by two tests: immunohistochemistry (IHC), which detects if cancer cells have a particular protein or marker on their surface, and fluorescence in situ hybridization (FISH), which detects a specific DNA sequence from cancer cells.

About ORPATHYS^®

ORPATHYS^® (savolitinib) is an oral, potent and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression.

ORPATHYS^® is approved in China for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. ORPATHYS^® also received a conditional approval in China for the treatment of adult patients with locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments. ORPATHYS^® in combination with TAGRISSO^® is approved in China for patients with locally advanced or metastatic EGFR mutation-positive non-squamous NSCLC with MET amplification after disease progression on EGFR TKI therapy based on the SACHI Phase III trial. The combination was also granted a temporary authorization in Switzerland for the treatment of patients with locally advanced or metastatic EGFRm NSCLC and high levels of MET overexpression or amplification who progressed on prior treatment with TAGRISSO^®. This was based on results from the global SAVANNAH Phase II trial. The global, randomized, SAFFRON Phase III trial in the same treatment setting comparing the combination with doublet platinum-based chemotherapy reported positive high-level results, demonstrating a statistically significant and clinically meaningful improvement in PFS and OS in August 2026.

About TAGRISSO^®

TAGRISSO^® (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including the treatment of central nervous system metastases.

TAGRISSO^® is approved as monotherapy in more than 120 countries including the US, EU, China and Japan. Approved indications include for first-line treatment of patients with locally advanced or metastatic EGFRm NSCLC, locally advanced or metastatic EGFR T790M mutation-positive NSCLC, adjuvant treatment of early-stage EGFRm NSCLC and locally advanced, unresectable NSCLC following platinum-based chemoradiation therapy. TAGRISSO^® is also approved in combination with chemotherapy in more than 80 countries, including the US, EU, China and Japan, for first-line treatment of patients with locally advanced or metastatic EGFRm NSCLC.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of ORPATHYS^®, the further clinical development for ORPATHYS^®, its expectations as to whether any studies on ORPATHYS^® would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of ORPATHYS^®, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of ORPATHYS^® for a targeted indication; the sufficiency of funding; HUTCHMED’s and AstraZeneca’s ability to successfully develop and commercialize ORPATHYS^®. In addition, as certain studies rely on the use of other drug products such as TAGRISSO^® as combination therapeutics with ORPATHYS^®, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of these therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

REFERENCES

1         World Health Organization. International Agency for Research on Cancer. Lung Fact Sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf. Accessed August 2026.

2         American Cancer Society. What Is Lung Cancer? Available at: https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html. Accessed August 2026.

3         Chen HJ, et al. Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI. Medicine. 2021;100(6):e24688.

4         Szumera-Ciećkiewicz A, et al. EGFR Mutation Testing on Cytological and Histological Samples in Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. Int J Clin Exp Pathol. 2013;6:2800-2812.

5         Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First- Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011;29:2121-2127.

6         Ellison G, et al. EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. J Clin Pathol. 2013;66:79-89.

7         Uchikawa E, et al. Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12(4074)

8         Wang Q, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019;63.